Eight major RCTs of GLP-1RAs have investigated the cardiovascular outcomes, including the ELIXA trial of lixisenatide (250), the EXSCEL trial of exenatide ER (251), the LEARDER trial of liraglutide (252), the SUSTAIN-6 trial of subcutaneous semaglutide (253), the HARMONY trial of albiglutide (228), the REWIND trial of dulaglutide (254), the PIONEER trial of oral semaglutide (255), and the SELECT trial of subcutaneous semaglutide (199)
DOI.org (Crossref) , Merchant, Warda, et al
Feeling like your metabolism works against you
Louis Health Care System reviewed the health records of two million veterans who were treated for diabetes from October 2017 through December 2023 to determine the GLP-1 medications effects on the bodys organ systems
The neuroprotective effects of GLP-1: possible treatments for cognitive deficits in individuals with mood disorders
This might even benefit you long term